Format

Send to

Choose Destination
J Pediatr Hematol Oncol. 2020 Feb 6. doi: 10.1097/MPH.0000000000001720. [Epub ahead of print]

Cell-free DNA Oncogene Copy Number as a Surrogate Molecular Biomarker in ALK/MYCN-coamplified Neuroblastoma.

Author information

1
Departments of Pediatric Hematology and Oncology.
2
Pediatrics.
3
Department of Pediatric Hematology and Oncology Research, Research Institute, National Center for Child Health and Development, Tokyo, Japan.
4
Clinical Laboratory, Hyogo Prefectural Amagasaki General Medical Center, Hyogo.

Abstract

Secondary expansion and/or evolution of aggressive subclones are associated with the disease progression and resistance to chemotherapy in neuroblastoma, and it is important to track the clonal changes during the treatment period. Cell-free (cf) DNA analysis, namely liquid biopsy, can detect the genomic change of tumor cells without surgical procedures. In this report, we showed that serial polymerase chain reaction-based cf DNA neuroblastoma proto-oncogene quantification is sensitive enough to evaluate the aggressive cellular characteristics of ALK/MYCN-coamplified neuroblastoma and stressed the promise of cf DNA analyses as a reliable molecular marker in advanced neuroblastoma.

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center